logo

For the Inventor, By the Inventor

Lexington, MA, United States of America

Gerald A Beltz

This inventor holds 10 USPTO granted patents and 1 EPO patent. Top assignees: Antigenics, Inc., Aquila Biopharmaceuticals Inc., Cambridge Bioscience Corporation. Active years: 1988-2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gerald A Beltz. Retrieved from https://idiyas.com/inventor/gerald-a-beltz

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10

% Patents Active = 60.0

 

Average Co-Inventor Count = 3.7

ph-index = 7

Forward Citations = 174(Granted Patents)


Company Filing History:

goldMedal5 out of 11 
 
Antigenics, Inc.
 patents
silverMedal3 out of 6 
 
Aquila Biopharmaceuticals Inc.
 patents
bronzeMedal1 out of 6 
 
Cambridge Bioscience Corporation
 patents
4. 1 out of 8 
 
Cambridge Biotech Corporation
 patents

Years Active: 1988-2013

Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents
1. 8461323 - Characterization of granulocytic ehrlichia and methods of use (2013-06-11),
2. 8435495 - Characterization of granulocytic Ehrlichia and methods of use (2013-05-07),
3. 8093008 - Characterization of granulocytic ehrlichia and methods of use (2012-01-10),
4. 7863434 - [object Object] (2011-01-04),
5. 6645495 - Compositions of saponin adjuvants and excipients (2003-11-11),
6. 6306394 - Nucleic acids, proteins, and methods of use of granulocytic ehrlichia (2001-10-23),
7. 6228608 - Recombinant FIV glycoprotein 160 and P24 gag protein (2001-05-08),
8. 6204252 - Characterization of granulocytic ehrlichia and methods of use (2001-03-20),
9. 5352449 - Vaccine comprising recombinant feline leukemia antigen and saponin (1994-10-04),
10. 4753873 - Peptides for the diagnosis of HTLV-III antibodies, their preparation and (1988-06-28),

Title: Gerald A. Beltz: Innovator in Granulocytic Ehrlichia Research

Introduction

Gerald A. Beltz is a notable inventor based in Lexington, MA (US), recognized for his contributions to the field of granulocytic ehrlichia research. With a total of 10 patents to his name, he has made significant advancements in understanding and diagnosing infections caused by granulocytic ehrlichia.

Latest Patents

Among his latest patents, Gerald A. Beltz has developed innovative methods related to the characterization of granulocytic ehrlichia. One of his key inventions focuses on polypeptides that contain antigenic epitopes from granulocytic ehrlichia (GE) proteins, which can be utilized in various applications. Another important patent involves methods for screening samples obtained from subjects for antibodies related to granulocytic ehrlichia infection, enhancing diagnostic capabilities in this area.

Career Highlights

Throughout his career, Gerald A. Beltz has worked with prominent companies such as Antigenics, Inc. and Aquila Biopharmaceuticals Inc. His work has contributed to the advancement of medical research and the development of effective diagnostic tools.

Collaborations

Gerald has collaborated with notable professionals in his field, including James Storey and Cheryl Murphy. These partnerships have further enriched his research and innovation efforts.

Conclusion

Gerald A. Beltz stands out as a significant figure in the realm of granulocytic ehrlichia research, with a strong portfolio of patents and collaborations that underscore his impact on medical science. His work continues to pave the way for advancements in diagnostics and treatment options.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…